Close



Apr 16, 2024 06:39AM
Feb 29, 2024 02:00AM
Feb 27, 2024 07:00AM
Jan 8, 2024 03:00AM
Nov 8, 2023 04:01PM
Nov 2, 2023 03:04AM
Oct 6, 2023 02:00AM Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023
Oct 3, 2023 02:00AM
Sep 11, 2023 05:41AM
Sep 11, 2023 02:00AM
Sep 6, 2023 02:00AM
Aug 31, 2023 05:51AM
Aug 31, 2023 02:00AM
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Aug 3, 2023 02:00AM
Jul 26, 2023 02:00AM
Jul 20, 2023 02:00AM
Jun 28, 2023 05:24AM
Jun 28, 2023 02:00AM
Jun 27, 2023 02:00AM
May 24, 2023 02:00AM Verona Pharma to Present at Jefferies Healthcare Conference
May 9, 2023 02:00AM
May 2, 2023 02:00AM
Apr 10, 2023 02:00AM
Mar 7, 2023 02:00AM
Feb 22, 2023 04:01PM
Dec 20, 2022 04:02AM
Dec 20, 2022 02:00AM Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Nov 9, 2022 02:00AM
Nov 7, 2022 04:01PM
Aug 9, 2022 06:24AM
Aug 9, 2022 03:00AM
Aug 9, 2022 02:00AM
Aug 8, 2022 04:01PM
Jun 9, 2022 02:00AM Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
May 9, 2022 02:00AM
May 3, 2022 05:55AM
May 3, 2022 02:00AM
Mar 3, 2022 02:00AM
Feb 17, 2022 04:01PM
Jan 24, 2022 02:00AM
Jan 6, 2022 02:00PM Franciosi Consulting Reviewing the Use of Psilocybin for Treating Depression, Anxiety and Addiction
Jan 5, 2022 02:00AM
Dec 16, 2021 05:57AM
Dec 16, 2021 02:00AM
Nov 9, 2021 02:00AM
Aug 5, 2021 02:00AM
May 12, 2021 07:00AM
Apr 29, 2021 02:00AM Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
Mar 4, 2021 04:01PM

251,639 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All